ArticleTranslational vision science & technology2021
Hierarchical Censored Bayesian Analysis of Visual Field Progression.
Article in Translational vision science & technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Using the Rate of Global and Pointwise Microperimetry Change to Predict Structural Conversion in Intermediate Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- A Bayesian Hierarchical Longitudinal Model for Estimation of Central Visual Field Rates of Change in Glaucoma.Translational vision science & technology · 2025Article
- A SPATIALLY VARYING HIERARCHICAL RANDOM EFFECTS MODEL FOR LONGITUDINAL MACULAR STRUCTURAL DATA IN GLAUCOMA PATIENTS.The annals of applied statistics · 2024Article
- Estimating the Distribution of True Rates of Visual Field Progression in Glaucoma.Translational vision science & technology · 2024Article
- A Bayesian Hierarchical Spatial Longitudinal Model Improves Estimation of Local Macular Rates of Change in Glaucomatous Eyes.Translational vision science & technology · 2024Article
- Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma.Translational vision science & technology · 2023Article
- Improving the Accuracy and Speed of Visual Field Testing in Glaucoma With Structural Information and Deep Learning.Translational vision science & technology · 2023Article
- Reply.Ophthalmology science · 2023Article
- Effect of trabeculectomy on the rate of progression of visual field damage.Eye (London, England) · 2023Article
- Static Perimetry in the Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A) Study: Assessment Through 2 Years.American journal of ophthalmology · 2023Observational
- The Usefulness of Assessing Glaucoma Progression With Postprocessed Visual Field Data.Translational vision science & technology · 2022Article
- UWHVF: A Real-World, Open Source Dataset of Perimetry Tests From the Humphrey Field Analyzer at the University of Washington.Translational vision science & technology · 2022Article
- A Joint Bayesian Longitudinal Model for Macular Structure-Function Correlations in Glaucoma.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop a Bayesian model (BM) for visual field (VF) progression accounting for the hierarchical, censored and heteroskedastic nature of the data. Methods: Three versions of a hierarchical BM were developed: a simple linear (Hi-linear); censored at 0 dB (Hi-censored); heteroskedastic censored (Hi-HSK). For the latter, we modeled the test variability according to VF sensitivity using a large test-retest cohort (1396 VFs, 146 eyes with glaucoma). We analyzed a large cohort of 44,371 VF tests from 3352 eyes from five glaucoma clinics. We quantified the bias in the estimated rate-of-progression, the detection of progression (Hit-rate [HR]), the median time-to-progression and the prediction error of future observations (mean absolute error [MAE]). HR and time-to-progression were compared at matched false-positive-rate (FPR), quantified using permutations of a separate test-retest cohort (360 tests, 30 eyes with glaucoma). BMs were compared to simple linear regression and Permutation-Analyses-of Pointwise-Linear-Regression. Differences in time-to-progression were tested using survival analysis. Results: Censored models showed the smallest bias in the rate-of-progression. The three BMs performed very similarly in terms of HR and time-to-progression and always better than the other methods. The average reduction in time-to-progression was 37% with the BMs (P < 0.001) at 5% FPR. MAE for prediction was very similar among methods. Conclusions: Bayesian hierarchical models improved the detection of VF progression. Accounting for censoring improves the precision of the estimates, but minimal effect is provided by accounting for heteroskedasticity. Translational Relevance: These results are relevant for quantification of VF progression in practice and for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.